Congrats to the Vividion team on a KEAP1 binder which unexpectedly turned out to be a KEAP1/CUL3 molecular glue to degrade NRF2. Unexpected activity since known binders inhibit KEAP1 rather than activate. Kudos to sticking with the data and expecting the unexpected! link below
Sourav Bandyopadhyay retweeted
Doing good science is 90% finding a science buddy to constantly talk to about the project.
I have benefited greatly from some amazing books that helped define my approach to science, startups and leadership. Delighted to pass them on! 1/5
First up Emperor of All Maladies by Siddharta Mukherjee. Amazingly written and captivating piece of the history of mankind’s battle with cancer. For me, so elegantly put our research into a broader context that it inspired me to double down my focus on cancer therapies 2/5
Hard Thing About Hard things by Ben Horowitz. Best encapsulation of the vision, dedication, and perseverance that a founder needs to have to be successful. Written for tech, but this vital information is applicable in any industry 4/5
Sourav Bandyopadhyay retweeted
A feature in @NatureBiotech discusses the rise in team size in academic science and how it has generated an unintended side effect: junior scientists are less likely to secure research funding or obtain tenure and are more likely to leave academia. 🔒 go.nature.com/4dtPTx1
In what started as a control experiment we were surprised to find transcriptional heterogeneity even in cancer cell lines, in ways that make certain subpopulations resistant to standard of care tx. nature.com/articles/s41598-0…
We also found in vivo and clinical evidence that cGAS signaling leads to poorer outcomes in breast cancer treated with chemo
Congrats to Mauricio Jacobo Jacobo and Hayley Donnella who drove the project and have both moved on from the lab and thanks to our wonderful collaborator @AndreiGoga_SF @UCSFCancer
Its been thrilling to see Rezo hitting its stride in mapping networks, prosecuting targets and drilling into drug discovery. Amazing things to come. We are excited to build the NextGen Sequence->Systems->Structures->Drugs platform!
Rezo is excited to be included among @biospace's NextGen Class of 2024! 2023 was an important year for Rezo and we look forward to carrying that same momentum into the new year as we seek to unlock a new era of #drugdiscovery. biospace.com/article/nextgen…
Great department and wonderful place to start your career!
You’re unable to view this Post because this account owner limits who can view their Posts. Learn more
Excited about the future of Rezo with such a seasoned and balanced leader at the helm, onwards!
We're excited to welcome Nadir Mahmood, Ph.D., as CEO and board member! His expertise will play a pivotal role as we seek to shift the way we understand disease biology through our integrated mapping of disease networks for precision therapeutics. businesswire.com/news/home/2…
Sourav Bandyopadhyay retweeted
We're excited to welcome Nadir Mahmood, Ph.D., as CEO and board member! His expertise will play a pivotal role as we seek to shift the way we understand disease biology through our integrated mapping of disease networks for precision therapeutics. businesswire.com/news/home/2…
New work from our group delineating biomarkers and indications for Rapalink, originally from @kevansf, now in the clinic with Revolution Medicines. This amazing Frankenstein-molecule can overcome acquired resistance to hormone tx and cdk4/6 inhibitors in ER+ breast cancers
💊@SBLabUCSF identified a new class of drugs that can be used to treat aggressive, treatment resistant #BreastCancers
🔬nature.com/articles/s41388-0…
#OpenAccess #mTOR
The fact that ADCs do not appear to require expression of the target antigen is a pet peeve of mine for years - new evidence that’s it’s effect is non specific and basically slow release chemo
One hypothesis is that ADCs act (in part) as slow payload release systems
CBX-12, a non-targeted peptide conjugated to Exatecan (payload ~DXd), showed 22% ORR in OC and 25% in BC #ASCO23
Normalized cytotoxin content:
CBX-12 ~0.15 mg/kg
T-DXd ~0.14 mg/kg
meetings.asco.org/abstracts-…
